How to Define Treatment Success or Failure if Tumors Do Not Shrink

摘要: The development of targeted anti cancer drugs in recent years puts a challenge on classical trial designs. In this chapter we point out that defining biological relevant dose might become more important than MTD and establishing the mechanism action becomes pivotal early drug development. Furthermore present examples trails show importance patient population likely to benefit from drugs.